HOOKIPA Pharma to Present at Kempen Life Science Conference
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a biopharmaceutical company focused on immunotherapeutics, announced its participation in the virtual Kempen Life Science Conference on April 21, 2021. The management team will host one-on-one meetings during the event. HOOKIPA is advancing a pipeline targeting virally mediated cancer antigens and infectious diseases, including its lead oncology candidates, HB-201 and HB-202, in Phase 1/2 trials. The company also collaborates with Gilead Sciences to explore functional cures for HIV and Hepatitis B infections, showcasing its innovative approach to immunotherapy.
- None.
- None.
NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and host 1:1 meetings at the virtual Kempen Life Science Conference, taking place April 21, 2021.
Additional information will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.
HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.
HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.
HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
| Media | Investors | |
| Nina Waibel | Matt Beck | |
| Senior Director - Communications | Executive Director - Investor Relations | |
| nina.waibel@hookipapharma.com | matthew.beck@hookipapharma.com |
FAQ
What is HOOKIPA Pharma participating in on April 21, 2021?
What clinical trials is HOOKIPA currently conducting?
What is the focus of HOOKIPA's research?
Who is HOOKIPA collaborating with for HIV research?
What type of technology does HOOKIPA utilize in its therapies?
